Central govt had proposed to apply trade margin rationalisation (TMR) approach to regulate prices of non-scheduled drugs, which would have resulted in capping trade margins.
New Delhi: A panel under the country’s drug pricing agency, the National Pharmaceutical Pricing Authority (NPPA), has flagged that the injectible version of a...
Drug price regulator's decision comes amid increase in approvals to fixed dose combination medicines or drug cocktails that it says could pose health hazard.
NPPA has issued a list of ‘overcharging cases’ under litigation, which includes matters dating back to 1997 & those where firms have moved court against the allegations.
An increasing number of fixed dose combination drugs is not desirable in the overall public interest and welfare, says the National Pharmaceutical Pricing Authority.
The NPPA observations came this week as it took up applications to fix the prices of 34 new drugs, most of which were fixed-dose combination medicines or drug cocktails.
NPPA has been seeking reports from industry bodies on complaints regarding violations of the self-regulatory mechanism meant to discourage pharma malpractices. But it said in reply to an RTI query that this isn't part of its mandate.
Representatives from NPPA, CDSCO and DGHS to be part of the standing committee, which will have mandate to approve the drug discontinuation applications.
Advice comes at a time when India accounts for a 5th of global generic drug supply & 40% of generics used in US. However, this strength in finished formulations relies on imported ingredients.
It’s easy to understand why the government can’t speak the hard truth. When this war ends, as all wars do, India’s interests will lie with both the winner and the loser.
COMMENTS